{"id":53324,"date":"2023-01-26T11:03:11","date_gmt":"2023-01-26T10:03:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-primary-immunodeficiency-therapeutics-strategic-business-report-2022-researchandmarkets-com\/"},"modified":"2023-01-26T11:03:11","modified_gmt":"2023-01-26T10:03:11","slug":"global-primary-immunodeficiency-therapeutics-strategic-business-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-primary-immunodeficiency-therapeutics-strategic-business-report-2022-researchandmarkets-com\/","title":{"rendered":"Global Primary Immunodeficiency Therapeutics Strategic Business Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Primary Immunodeficiency Therapeutics: Global Strategic Business Report”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global market for Primary Immunodeficiency Therapeutics estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027.\n<\/p>\n

\nAntibody Deficiency, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$6.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 7-year period.\n<\/p>\n

\nThe U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.9% CAGR<\/strong>\n<\/p>\n

\nThe Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027.\n<\/p>\n

\nAmong the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.\n<\/p>\n

\nInnate Immune Disorders Segment to Record 6.2% CAGR<\/strong>\n<\/p>\n

\nIn the global Innate Immune Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$669.8 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.\n<\/p>\n

\nSelect Competitors (Total 47 Featured) –<\/strong>\n<\/p>\n